A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis



Status:Recruiting
Conditions:Psoriasis
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:18 - 70
Updated:1/27/2019
Start Date:November 20, 2018
End Date:December 2019
Contact:Cherie Robbins, BScN
Email:clinicaltrialsinfo@anaptysbio.com
Phone:858-362-6295

Use our guide to learn which trials are right for you!

A Phase II, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis

A study to evaluate the efficacy and safety, and pharmacokinetic (PK) profile of multiple
doses of ANB019 in subjects with Palmoplantar Pustulosis (PPP)

This study is a Phase II, randomized, placebo-controlled, double-blind, multiple dose study
to evaluate the efficacy and safety, and PK of ANB019 in subjects with Palmoplantar
Pustulosis

Inclusion Criteria:

- Clinically confirmed diagnosis of PPP

- Disease duration of at least 6 months prior to screening

- Present with active pustules on palms or/and soles at screening

Exclusion Criteria:

- Any other ongoing inflammatory disease that interfere with the investigator's ability
to evaluate the subject's response to therapy

- History of recurrent or active/serious infection

- Ongoing use of psoriasis prohibited medication

Other protocol-defined inclusion/exclusion criteria may apply
We found this trial at
2
sites
Indianapolis, Indiana 46260
1868
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
Wilmington, North Carolina 28403
2455
mi
from 98109
Wilmington, NC
Click here to add this to my saved trials